logo

(ITEK)



Trade ITEK now with
  Date
  Headline
12/16/2019 7:07:13 AM Rocket Pharmaceuticals Receives EMA PRIME Eligibility for RP-L102 Gene Therapy For Fanconi Anemia
12/13/2019 4:07:44 PM Rocket Pharmaceuticals Announces Closing Of Public Offering
12/10/2019 10:53:23 PM Rocket Pharma Prices Underwritten Public Offering Of 3.82 Mln Shares At $22.25/shr
12/10/2019 4:03:17 PM Rocket Pharmaceuticals Announces Proposed Public Offering Of Common Stock
12/9/2019 7:03:10 AM Rocket Pharma Announces Preliminary Data From Phase 1/2 Trial Of RP-L201 For Leukocyte Adhesion Deficiency-I
12/8/2019 7:42:20 PM Rocket Pharma : Data Provides Evidence On Potential Of Commercial-grade 'Process B' Product In Treating Fanconi Anemia
10/24/2019 8:21:46 AM Rocket Pharma Presents Updated Long-term Follow-up From The Phase 1/2 Clinical Trial Of RP-L102 At ESGCT
10/22/2019 7:22:36 AM Rocket Pharma Announces Clearance Of IND For RP-L301 Gene Therapy For Pyruvate Kinase Deficiency
9/23/2019 7:05:52 AM Rocket Pharma Announces IMPD Clearance Of RP-L301 Gene Therapy For Pyruvate Kinase Deficiency
9/5/2019 7:26:29 AM Rocket Pharma Announces First Patient Treated In Phase 1/2 Registrational Trial Of RP-L201 For LAD-I
6/18/2019 7:05:49 AM Rocket Pharma Announces Patient Dosing Has Commenced In Phase 1 Clinical Trial Of RP-A501
4/15/2019 10:48:15 PM Rocket Pharma Prices Underwritten Public Offering Of 4.50 Mln Shares At $17.50/shr
3/12/2019 7:03:53 AM Rocket Pharma Announces First Patient Dosed In Phase 1 Clinical Trial Of RP-L102 In The U.S.
3/7/2019 7:07:37 AM Rocket Pharma Posts Q4 Net Loss Of $27.3 Mln Or $0.66/Shr Vs Loss $6.7 Mln Or $0.98/Shr Last Year
1/22/2019 7:04:43 AM Rocket Pharma Announces Clearance Of IND For RP-A501 Gene Therapy For Danon Disease
11/28/2018 7:38:00 AM RTW Investments Announces Purchase Of 967,742 Common Shares Of Rocket Pharmaceuticals Through Private Placement
11/27/2018 8:07:49 PM Rocket Pharma Prices Public Offering Of 3.55 Million Shares At $15.50/shr
11/26/2018 8:41:48 AM Rocket Pharmaceuticals Announces Preclinical Data For AAV-Based RP-A501
11/26/2018 8:39:32 AM Rocket Pharma, REGENXBIO Unveil License Agreement For Treatment Of Danon Disease Using NAV AAV9 Vector